Notice of Termination of Master Development and Toll Manufacturing Agreement between Endo Pharmaceuticals Inc. and Novartis Consumer Health, Inc.
Endo Pharmaceuticals Inc. is formally notifying Novartis Consumer Health, Inc. of its decision to terminate their Master Development and Toll Manufacturing Agreement, originally signed on May 3, 2001, as amended. This termination notice is issued in accordance with the terms specified in the agreement. The letter is sent by Endo's Chief Operating Officer and serves as the official communication ending the business relationship under this contract.
Exhibit 10.39.3
February 23, 2011
VIA ELECTRONIC MAIL & OVERNIGHT MAIL
Mr. Greg Tole
General Counsel
Novartis Consumer Health, Inc.
200 Kimball Drive
Parisppany, NJ 07054-0622
| Re: | Termination of Master Development and Toll Manufacturing Agreement |
Dear Mr. Tole:
Pursuant to Section 19.1.2 of that certain Master Development and Toll Manufacturing Agreement, dated May 3, 2001, by and between Novartis Consumer Health, Inc. and Endo Pharmaceuticals Inc. (“Endo”), as amended, this letter shall serve as Endo’s Notice of Termination of such agreement.
Sincerely,
/s/ Julie McHugh
Julie McHugh
Chief Operating Officer
| cc: | Steven Cowan |
